Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution

Glucotrack, Inc.

Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.
Approximately 4,300 Series A Warrants remain outstanding; company expects to buy back most of those.
Series B Warrants had been previously extinguished in exchange for common stock as of March 31, 2025.
Buyback eliminates warrant liability accounting and reduces future share dilution overhang.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.